US and International Prescription Drug Labeling: Comparisons and Important Updates

Preconference Workshop: December 7, 2010
Conference: December 8-9, 2010
Embassy Suites DC Convention Center | Washington, DC, USA

PROGRAM COMMITTEE
Steven W. Bass, PhD
President
Bass BioPharm Consulting Group, LLC, US

Bruce Boulton, MSC
Product Information Officer
Health Canada, Canada

Laurie Burke, MPH, RPh
Director, Study Endpoints and Labeling Development,
Office of New Drugs,
CDER, FDA, United States

Dr. med Leander Fontaine
President
Pharmiceutics, LLC., US

Dianne Kennedy, MPH, RPh
Consumer Safety Officer,
Study Endpoints and Labeling Development,
Office of New Drugs,
CDER, FDA, United States

Barbara Lachmann, MD
Senior Labeling Advisor, Merck KGaA, Germany

Rie Matsui, RPh
Senior Manager
Post Marketing Regulatory Strategy
Regulatory Affairs, Development Japan
Pfizer Japan Inc.

Dr. med Klaus Menges
Head of Unit Scientific Quality Assurance and Process Organisation, BfArM, Germany

Junko Sato, PhD
Director for Risk Management, Office of Safety II
Pharmaceuticals and Medical Devices Agency (PMDA) Japan

Join Regulatory Authorities from Different Regions to Discuss Key Labeling Requirements, Recommendations, Trends, and New Developments.

This conference will discuss issues commonly encountered by industry in an effort to advance understanding of labeling requirements across various regions (Canada, European Union, Japan, and US).

PRECONFERENCE WORKSHOPS — December 7
• Separate registration is required. See registration page.
• Review of the EU PIM System (Product Information Management System) from a Practical Regulatory Perspective
• Structured Product Labeling and eList
• US Prescribing Information – Writing the Highlights Section
• US Prescribing Information – Writing the Boxed Warning, Contraindications, Warnings and Precautions and Adverse Reactions sections

MAIN CONFERENCE — December 8-9

SESSION TOPICS
• High Level Comparison of the Approaches to Prescription Drug Labeling: Canada, European Union, Japan, and US
• Comparative Review of the Content of the Indications and Clinical Studies Section
• Comparative Review of the Content of the Adverse Reactions Section
• Comparative Review of the Content of the Warnings and Precautions, Contraindications and Boxed Warnings Sections
• Comparative Review of Content of the Interactions
• Comparative Review of Approaches to Patient Information: Canada, European Union, Japan, and US
• Hot Topics — Important Labeling News and Developments: Canada, European Union, Japan, and US

WHO SHOULD ATTEND
Professionals from biopharmaceutical companies, CROs, consulting agencies, and regulatory authorities involved in:
• Labeling
• Clinical safety/Pharmacoepidemiology/Pharmacovigilance
• Regulatory affairs/Drug Review and Approval Process
• Medical affairs/Clinical research & development
• Product research & development alliances
• Quality control/Quality assurance

EVENT INFORMATION
Contact Colleen Braun, Program Developer
Phone 215.442.6160 / Fax 215.442.6199
email Colleen.Braun@diahome.org

Member Early-bird Rate – Register by November 12 and SAVE $150!
CONTINUING EDUCATION CREDITS

Accreditation Council for Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and the Drug Information Association. PIM is accredited by the ACCME to provide continuing medical education for physicians.

PIM designates this educational activity for a maximum of 13.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is designated for 13.75 contact hours or 1.375 continuing education units (CEUs).

286-000-10-038-L04-P

Type of Activity: Knowledge

Drug Information Association has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102; (703) 506-3275.

Drug Information Association is authorized by IACET to offer 2.2 CEUs for this program.

CE Breakdown:

Preconference workshop: 8 IACET CEUs

Conference: 13.75 AMA PRA Category 1 Credit(s)™, 13.75 ACPE contact hours or 1.375 CEUs; 1.4 IACET CEUs

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) and DIA require instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM and DIA for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

LEARNING OBJECTIVES

At the conclusion of this meeting, participants should be able to:

• Discuss labeling requirements and their differences in Canada, EU, Japan, and US
• Explain how adverse reactions are selected for inclusion in labeling in Canada, EU, Japan, and US
• Describe new developments in labeling in Canada, EU, Japan, and US
• Outline how regulatory information on medicinal products is made available for health care professionals and patients in Canada, EU, Japan, and US

PRECONFERENCE WORKSHOP | DECEMBER 7, 2010

7:30-8:00 AM REGISTRATION AND CONTINENTAL BREAKFAST

8:00-10:00 AM TUTORIAL 1

Review of the EU PIM System (Product Information Management System) from a Practical Regulatory Perspective

Use case for PIM as the electronic labeling system for the EU and its implementation for centrally authorized products.

Dr. med Klaus Menges
Head of Unit Scientific Quality Assurance and Process Organisation BfArM, Germany

Challenges and Key Considerations for Companies in Preparation for PIM

Barbara Lachmann, MD
Senior Advisor Global Labeling
Merck KGaA, Germany

This tutorial will review the approach towards electronic management of authoring, exchange and assessment of product information texts for products authorized via the centralized procedure in the European Union and will detail the resulting benefits for both regulators and companies.

LEARNING OBJECTIVES

• Explain the benefits of PIM for both companies and regulators
• Describe the principles of PIM and its foreseen implementation for centrally authorized products in the EU
• Recognize points to be considered for migration of product information into the PIM system
• Describe the workflow for review of product information between companies and regulators via the PIM system

10:00-10:15 AM REFRESHMENT BREAK

10:15 AM-12:15 PM TUTORIAL 2

Structured Product Labeling and eList

FACULTY:

Lonnie Smith
Policy Analyst
Data Standards Council & Office of Critical Path Programs, Office of the Commissioner
FDA, United States

Stuart J. Nelson, MD, FACMI
Head, Medical Subject Headings
National Library of Medicine

This tutorial will provide authors of Structured Product Labeling (SPL) documents with the knowledge to create SPL documents submitted to FDA in compliance with the Electronic Labeling Rule and section 224 of the FDA Amendments Act 2007.

LEARNING OBJECTIVES

• Write valid and compliant SPL documents with content of labeling in Physician’s Labeling Rule (PLR) and non-PLR format
• Describe the impact of FDA Amendments Act 2007 - section 224 Electronic Registration and Listing on content of labeling documents submitted in SPL format.
• Explain the utility of SPL as an Health Level Seven data standard for the exchange of content of labeling information.
## US Prescribing Information – Writing the Highlights Section

**FACULTY:**
- Debra Beitzell, BSN
  Labeling Initiatives Specialist, Study Endpoints and Labeling Development, Office of New Drugs, CDER, FDA, United States
- Jeanne Delasko, RN, MS
  Labeling Initiatives Specialist, Study Endpoints and Labeling Development, Office of New Drugs, CDER, FDA, United States
- Jill Lindstrom, MD
  Lead Medical Officer, Division of Dermatology and Dental Products, Office of New Drugs, CDER, FDA, United States

The Highlights (HL) section of US labeling is found at the beginning of the Prescribing Information (PI). The HL section is a half-page, concise summary of the most crucial information found in the PI. In this tutorial, participants will be taught the requirements for a HL section and will help develop a HL section based on an example PI.

**LEARNING OBJECTIVES:**
- Discuss the US regulatory requirements for the HL section of labeling
- Identify common mistakes made when writing a HL section
- To identify the most important information in the PI and write a concise summary of that information in a HL section

## US Prescribing Information – Writing the Adverse Reactions, Warnings and Precautions, Contraindications and Boxed Warning sections

**FACULTY:**
- Theresa Kehoe, MD
  Medical Officer Team Leader, Division of Reproductive and Urologic Products, Office of New Drugs, CDER, FDA, United States
- Iris P. Masucci, PharmD
  Office of Medical Policy, CDER, FDA, United States
- Jun Yan, PharmD
  Labeling Initiatives Specialist, Study Endpoints and Labeling Development, Office of New Drugs, CDER, FDA, United States

In the Full Prescribing Information (PI) of US labeling, safety information is found in four different sections: Adverse Reactions, Warnings and Precautions, Contraindications and Boxed Warnings. In this tutorial, participants will be taught the requirements for each of these sections and will help develop these sections based on an example PI.

**LEARNING OBJECTIVES:**
- Explain the US regulatory requirements for the Adverse Reactions, Warnings & Precautions, Contraindications and Boxed Warnings sections of labeling and become familiar with applicable US guidance
- Identify the types of adverse reactions that belong in each section and what information to not include in these sections
- Describe common mistakes made when writing these sections

## CONFERENCE DAY 1 | DECEMBER 8, 2010

### 7:15-8:00 AM REGISTRATION AND CONTINENTAL BREAKFAST

### 8:15-9:00 AM SESSION 1

**High Level Comparison of the Approaches to Prescription Drug Labeling and the Dissemination of Related Regulatory Information: Canada, European Union, Japan, and USA**

**CHAIR:**
Laurie Burke, MPH, RPh
Director, Study Endpoints and Labeling Development, Office of New Drugs, CDER, FDA, United States

**Dr.med Leander Fontaine**
President, Pharmiceutics, LLC., United States

This session will introduce participants to the main commonalities and differences in the approach to providing healthcare professional information and patient information for prescription drugs in Canada, Europe, Japan, and USA. Focus is on the type of labeling documents and how they reach the intended audience.

**PARTICIPANTS SHOULD BE ABLE TO:**
- Name the healthcare professional labeling documents in the 4 markets
- Explain the role of manufacturers in the creation, maintenance and distribution of patient labeling in the 4 markets

### 9:00-10:30 AM SESSION 2

**Comparative Review of the Indications and Clinical Studies Sections: Canada, European Union, Japan and United States**

**CHAIR:**
Barbara Lachmann, MD
Global Regulatory Product Information, Merck KGaA Darmstadt, Germany

This session will provide a comparison of the rules for selecting content for the equivalents of the Indications and Clinical Studies sections in Canada, Europe, Japan, and USA. Main emphasis is on how to describe the indication, other descriptors of target population for use and limitations of use, which types of studies to include, and how much detail and information on their limitations to provide. The speakers will also describe if and by which means additional information on the agency’s assessment of a product is made available to the public (e.g. in the form of public assessment reports posted on an agency’s website).

**SPEAKERS:**
- Bruce Boulton, MSC
  Assessment Officer, Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD), Therapeutic Products Directorate, Health Canada, Canada
- Theresa Kehoe, MD
  Medical Officer Team Leader, Division of Reproductive and Urologic Products, Office of New Drugs, CDER, FDA, United States
- Iris P. Masucci, PharmD
  Office of Medical Policy, CDER, FDA, United States
- Jun Yan, PharmD
  Labeling Initiatives Specialist, Study Endpoints and Labeling Development, Office of New Drugs, CDER, FDA, United States

**LEARNING OBJECTIVES:**
- Describe the main differences in the use of electronic labeling formats in the 4 markets
- Define the acronyms used in the subsequent sessions
Dr. med Klaus Menges  
Head of Unit Scientific Quality Assurance and Process Organisation  
BfArM, Germany

Junko Sato, PhD  
Director for Risk Management, Office of Safety II  
PMDA, Japan

Ann Marie Trentacosti, MD  
Medical Officer, Study Endpoints and Labeling Development  
Office of New Drugs, CDER, FDA, United States

PARTICIPANTS SHOULD BE ABLE TO:
• Describe the main commonalities and differences in the approach to providing information on clinical studies
• Explain where and how regulatory authorities release additional information about their assessment to the public
• Explain how product labeling describes the intended target population for a product

10:30-11:00 AM REFRESHMENT BREAK

11:00 AM-1:00 PM SESSION 3  
Comparative Review of the Adverse Reactions Section: Canada, European Union, Japan and United States
CHAIR:
Dr. med Leander Fontaine  
President  
Pharmaceutics, LLC., United States

The session will review the guidance for selecting information for inclusion in the Adverse Reaction Section of labeling; including deciding which items should be included in labeling as “adverse reactions for the purposes of labeling.” The speakers will explain how to describe adverse reactions in labeling and how the presentation of adverse reactions information is structured. They will also explain how the probability of adverse reactions is illustrated in their local labeling.

SPEAKERS:
Bruce Boulton, MSC  
Assessment Officer  
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)  
Therapeutic Products Directorate  
Health Canada, Canada

Laurent Brassart, MD  
Scientific Administrator  
Information Compliance and Consistency  
Medical Information Sector  
European Medicines Agency

Hiromi Sadasue, MS  
Reviewer, Office of Safety II  
PMDA, Japan

Ellis Unger, MD  
Deputy Director, Office of Drug Evaluation I, Office of New Drugs, CDER, FDA, United States

PARTICIPANTS SHOULD BE ABLE TO:
• Explain the difference between adverse reactions for the purposes of labeling and “mere events”
• Explain how to describe adverse reactions selected for inclusion in labeling across Canada, Europe, Japan, and US
• Describe the differences in the standard approaches to illustrating the probability of adverse reactions across Canada, Europe, Japan, and US

2:00-3:30 PM SESSION 4  
Comparative Review of the Warnings and Precautions, Contraindications, and Boxed Warnings Sections: Canada, European Union, Japan and United States
CHAIR:
Dr. med Leander Fontaine  
President  
Pharmaceutics, LLC., United States

The speakers will explain the criteria for elevating adverse reactions to Warnings and Precautions, or Boxed Warnings and for contraindicating the use of a product in a population subset.

SPEAKERS:
Bruce Boulton, MSC  
Assessment Officer  
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)  
Therapeutic Products Directorate  
Health Canada, Canada

Laurent Brassart, MD  
Scientific Administrator  
Information Compliance and Consistency  
Medical Information Sector  
European Medicines Agency

Hiromi Sadasue, MS  
Reviewer, Office of Safety II  
PMDA, Japan

Ellis Unger, MD  
Deputy Director, Office of Drug Evaluation I, Office of New Drugs, CDER, FDA, United States

PARTICIPANTS SHOULD BE ABLE TO:
• Discuss the differences and commonalities in the criteria for adding risks to the local equivalents of the Warnings and Precautions section across Canada, Europe, Japan, and US
• Describe the criteria for contraindicating the use of a product in a population subset in Canada, Europe, Japan, and US
• Explain the differences in the approach to labeling “hypersensitivity contraindications”
• Recognize when to include a Boxed Warning (or statement with equivalent emphasis) and what information to include across Canada, Europe, Japan, and US

3:30-4:00 PM REFRESHMENT BREAK

4:00-5:30 PM SESSION 5  
Comparative Review of the Interactions Section: Canada, European Union, Japan, and USA
CHAIR:
Rie Matsui, RPh  
Senior Manager  
Post Marketing Regulatory Strategy  
Regulatory Affairs, Development Japan  
Pfizer Japan Inc.

This session will provide a comparison of the rules (evidentiary standard, relevance criteria and other factors) for determining which items should be included in labeling as “clinically significant/relevant interactions” in Canada, Europe, Japan, and US.

1:00-2:00 PM LUNCHEON
PARTICIPANTS WILL BE ABLE TO:

• Discuss similarities in the evidentiary standard across Canada, Europe, Japan, and US
• Identify the important categories of interactions
• Describe cross-labeling issues for interactions

SPEAKERS:

Bruce Boulton, MSC
Assessment Officer
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)
Therapeutic Products Directorate
Health Canada, Canada

Dr.med Klaus Menges
Head of Unit Scientific Quality Assurance and Process Organisation
BfArM, Germany

Eri Sugiyama, MS
Reviewer, Office of Safety II
PMDA, Japan

Suresh Doddapaneni, PhD
Clinical Pharmacologist, Office of Clinical Pharmacology
CDER, FDA, United States

CONFERENCE DAY 2 | DECEMBER 9, 2010

7:15-8:00 AM REGISTRATION AND CONTINENTAL BREAKFAST

8:30-10:00 AM SESSION 6

Comparative Review of Approaches to Patient Information: Canada, European Union, Japan, and USA

CHAIR:
Barbara Lachmann, MD
Global Regulatory Product Information
Merck KGaA Darmstadt, Germany

This session will provide a comparison of the approaches to providing agency-approved information to patients. The character of the information (e.g., the extent of the description of a product’s safety profile) will be discussed, as well as efforts to provide information that is understandable and readable for a lay audience.

SPEAKERS:

Bruce Boulton, MSC
Assessment Officer
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)
Therapeutic Products Directorate
Health Canada, Canada

Dr.med Klaus Menges
Head of Unit Scientific Quality Assurance and Process Organisation
BfArM, Germany

Hazuki Takaura, MS
Reviewer, Office of Safety II, PMDA, Japan

Denise M. Hinton, RN, BSN
Office of Medical Policy, CDER, FDA, United States

PARTICIPANTS SHOULD BE ABLE TO:

• Recognize differences in the extent of risk information included in patient information in Canada, Europe, Japan, and US
• Describe to what extent patient information is controlled by regulatory authorities in Canada, Europe, Japan, and US
• Explain the requirements for verifying readability of patient information in Canada, Europe, Japan, and US
Structured Product Labeling Update
Lonnie Smith  
Policy Analyst  
Data Standards Council & Office of Critical Path Programs  
Office of the Commissioner  
FDA, United States

2:30-3:00 PM  REFRESHMENT BREAK

3:00-4:30 PM  SESSION 8  
General Question & Answer Session

MODERATORS:
Steven W. Bass, PhD  
President  
Bass BioPharm Consulting Group, United States
Bruce Boulton, MSC  
Assessment Officer  
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)  
Therapeutic Products Directorate  
Health Canada, Canada

Laurie Burke, MPH, RPh  
Director, Study Endpoints and Labeling Development,  
Office of New Drugs,  
CDER, FDA, United States  

Dr.med Leander Fontaine  
President  
Pharmiceutics, LLC., United States

Rie Matsui, RPh  
Senior Manager  
Post Marketing Regulatory Strategy  
Regulatory Affairs, Development Japan  
Pfizer Japan Inc.

Dr.med Klaus Menges  
Head of Unit Scientific Quality Assurance and Process Organisation  
BfArM, Germany

This session provides an opportunity for the audience to ask any questions on prescription drug labeling in Canada, Europe, Japan, and USA. Registered attendees will be invited to submit questions in advance.

4:30-5:00 PM  WRAP UP/CONFERENCE ADJOURN

UPCOMING CONFERENCES AND TRAINING COURSES

CONFERENCES
OCTOBER 26-27, 2010  
Ensuring Quality and Balancing Risks for Multiregional Clinical Trials: Statistical, Clinical, Regulatory, and Ethical Factors  
Bethesda, MD
OCTOBER 26-27, 2010  
Tomorrow’s Project Manager: Evolving Competencies for Biopharmaceutical Professionals  
Bethesda, MD
OCTOBER 28-29, 2010  
The 9th Annual Electronic Submissions Conference: Working Together Towards a Global Strategy  
San Diego, CA
NOVEMBER 3-5, 2010  
DIA’s 8th Annual Canadian Meeting: Fostering Innovation and Access to Drugs  
Ottawa, CANADA
NOVEMBER 4-5, 2010  
DIA/FDA Orphan Drug Designation Workshop  
Lansdowne, VA
NOVEMBER 8-10, 2010  
Sustaining Clinical Trial Disclosure  
National Harbor, MD
DECEMBER 7-9, 2010  
US and International Prescription Drug Labeling: Comparisons and Important Updates  
Washington, DC

TRAINING COURSES
NOVEMBER 8-10, 2010  
Introduction to Good Clinical Practices and Auditing  
Horsham, PA
NOVEMBER 11-12, 2010  
Regulatory Affairs in Biologics  
Horsham, PA
NOVEMBER 15-16, 2010  
Premarketing Clinical Safety and Pharmacovigilance  
Horsham, PA
NOVEMBER 15-17, 2010  
Clinical Project Management  
Horsham, PA
NOVEMBER 15-18 2010  
Regulatory Affairs Part I: The IND Phase and Part II: The NDA Phase  
Baltimore, MD
NOVEMBER 17-18, 2010  
Postmarketing Drug Safety and Pharmacovigilance  
Horsham, PA
NOVEMBER 18-19, 2010  
Project Risk Management  
Horsham, PA
NOVEMBER 19, 2010  
Introduction to Signal Detection and Data Mining  
Horsham, PA

Visit www.diahome.org for a complete listing of upcoming events.
# US and International Prescription Drug Labeling Comparisons and Important Updates

**Event #10022 • Preconference: December 7 • Conference: December 8-9, 2010**  
Washington, DC, USA

## Registration Fees

If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.

<table>
<thead>
<tr>
<th>Member Early-bird Opportunity</th>
<th>On or before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Available on nondiscount member fee only</td>
<td>NOV. 12, 2010</td>
<td>NOV. 12, 2010</td>
</tr>
</tbody>
</table>

**Member Fee**  
US $1310 ❑ US $1460 ❑

Join DIA now to qualify for the early-bird member fee!  
www.diahome.org/Membership

**Nonmember Fee**  
US $1600 ❑

A one-year membership to DIA is available to those paying a nonmember registration fee. If paying a nonmember fee, please indicate if you do, or do not, want membership.

I want to be a DIA member ❑  I do NOT want to be a DIA member ❑

## Discount Fees

<table>
<thead>
<tr>
<th>Discount Fees</th>
<th>MEMBER</th>
<th>NONMEMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government (Full-time)</td>
<td>US $580 ❑</td>
<td>US $720 ❑</td>
</tr>
<tr>
<td>Charitable Nonprofit/Academia (Full-time)</td>
<td>US $730 ❑</td>
<td>US $870 ❑</td>
</tr>
</tbody>
</table>

*If paying a nonmember fee, please check one box above, indicating whether you want membership.

## PRECONFERENCE: Tuesday, December 7

US $710 ❑

## TO RECEIVE A TABLETOP EXHIBIT APPLICATION, PLEASE CHECK ❑

### GROUP DISCOUNTS*

Register 3 individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred. Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia.

To take advantage of this offer, please make a copy of this registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.

- Please indicate that this form is part of a group registration by checking this box and list below the names of the other three registrants from your company.
  1. [ ]
  2. [ ]
  3. [ ]

Payment options: Register online at www.diahome.org or check payment method.

- **CREDIT CARD** number may be faxed to: +1.215.442.6199. You may prefer to pay by check or bank transfer since non-U.S. credit card payment will be subject to the currency conversion rate at the time of the charge.
  - Visa ❑ MC ❑ AMEX ❑ Exp Date __________

Card # ____________________________

Signature __________________________

- **CHECK** drawn on a US bank payable to and mailed along with this form to: Drug Information Association Inc. P.O. Box 95000-1240, Philadelphia, PA 19195-1240, USA. Please include a copy of this registration form to facilitate identification of attendee.

- **BANK TRANSFER** When DIA completes your registration, an email will be sent to the address on the registration form with instructions on how to complete the Bank Transfer. Payment should be made in US dollars. Your name and company, as well as the Event ID, must be included on the transfer document to ensure payment to your account.

## TRAVEL AND HOTEL

The most convenient airport is BWI Airport or Dulles Airport and attendees should make airline reservations as early as possible to ensure availability. The Embassy Suites DC Convention Center Hotel is holding a block of rooms at the reduced rate below until November 12, 2010, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.

<table>
<thead>
<tr>
<th>Single</th>
<th>Double</th>
</tr>
</thead>
<tbody>
<tr>
<td>$234</td>
<td>$259</td>
</tr>
</tbody>
</table>

Please contact the Embassy Suites DC Convention Center Hotel by telephone at +1.202.739.2001 and mention the DIA event. The hotel is located at 900 10th Street, NW, Washington, DC 20001, USA.

## CANCELLATION POLICY:

On or before DECEMBER 1, 2010

**Administrative fee that will be withheld from refund amount:**

- Member or Nonmember = $200
- Government or Academia or Nonprofit (Member or Nonmember) = $100
- Tutorial (if applicable) = $50

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for canceling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

### Participants with Disabilities:

DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.

## EVENT INFORMATION

Contact Wendy Moyer, Program Manager, Phone +1.215.293.5810  
Fax +1.215.442.6199, email Wendy.Moyer@diahome.org

## TABLETOP EXHIBIT INFORMATION

Attendees may visit the tabletop exhibits during the event and receptions.

Contact Shannon Lewis, Exhibits Associate, Phone +1.215.442.6149  
Fax +1.215.442.6199, email Shannon.Lewis@diahome.org

Please check the applicable category:

- [ ] Academia
- [ ] Government
- [ ] Industry
- [ ] CSO
- [ ] Student

*(Call for registration information)*

**Last Name**

**First Name**

**Degrees**

- Dr. ❑  Mr. ❑  Ms. ❑

**Job Title**

**Company**

**Address** (As required for postal delivery to your location)

City  State  Zip/Postal  Country

email [ ] Required for confirmation

**Phone Number**

**Fax Number** [ ] Required for confirmation